Expand TEVA Menu
TEVA MENU

TEVA Latest Press Releases

-- March 31, 2025 --

New Data Strengthens Teva's Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable Globe Newswire 1:00 PM

-- March 27, 2025 --

Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025 Globe Newswire 4:30 PM
Teva Releases Q1 2025 Aide Memoire Globe Newswire 4:30 PM

-- March 3, 2025 --

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March Globe Newswire 4:30 PM

-- February 27, 2025 --

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals Globe Newswire 8:00 AM

-- February 25, 2025 --

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder Globe Newswire 4:00 PM

-- February 22, 2025 --

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn's Disease Globe Newswire 2:20 AM

-- February 21, 2025 --

Teva and Alvotech Announce SELARSDI (ustekinumab-aekn) Injection Now Available in the U.S. Globe Newswire 6:00 AM

-- February 18, 2025 --

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO) Globe Newswire 4:30 PM
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea (aflibercept) Globe Newswire 6:00 AM

-- January 29, 2025 --

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth Globe Newswire 7:00 AM

-- January 27, 2025 --

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi and Simponi Aria (golimumab) Globe Newswire 6:00 AM

-- January 13, 2025 --

Teva Announces Collaboration to Commercialize Formycon's Biosimilar Candidate to Eylea (aflibercept) in major parts of Europe and in Israel Globe Newswire 1:00 AM

-- January 10, 2025 --

Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI (eculizumab-aagh) in the United States Globe Newswire 8:30 AM

-- December 23, 2024 --

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference Globe Newswire 4:30 PM

-- December 20, 2024 --

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025 Globe Newswire 4:30 PM

-- December 17, 2024 --

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease Globe Newswire 7:30 AM

-- December 11, 2024 --

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients Globe Newswire 8:00 AM

-- December 5, 2024 --

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan Globe Newswire 6:00 PM

-- December 4, 2024 --

Teva Presents Positive Efficacy and Safety Data of AJOVY (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial Globe Newswire 2:00 AM

-- November 25, 2024 --

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference Globe Newswire 6:00 PM

-- November 8, 2024 --

Teva to Present at the Jefferies London Healthcare Conference Globe Newswire 4:30 PM

-- November 6, 2024 --

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS Globe Newswire 7:00 AM